📰 Active Biotech News
Page 3 - Active Biotech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Active Biotech. Real-time updates on events, politics, business and more.
March 25, 2022
Investegate announcements from Active Biotech, Correction: Active Biotech Year End Report 2021
February 10, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
February 9, 2022
Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents
February 9, 2022
Investegate announcements from Active Biotech, Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis
February 9, 2022
Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute...
February 9, 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular
February 9, 2022
Investegate announcements from Active Biotech, Active Biotech: Year End Report 2021
January 4, 2022
Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022. He will join the
December 15, 2021
Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the
December 10, 2021
Lund, December 10, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the